Association Between Serum Amyloid A Expression and Disease Control after Endoscopic Sinus Surgery in Patients With Chronic Rhinosinusitis With Nasal Polyps

Abstract

Objective

Our previous study revealed that serum amyloid A (SAA) levels in polyp tissues could serve as a biomarker for the prediction of corticosteroid insensitivity in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). However, their association with disease control status in the patients after endoscopic sinus surgery remains to be assessed.

Methods

Polyp tissues and control uncinate process mucosa were collected from 48 patients with CRSwNP and 10 healthy control subjects. SAA expression was examined using immunohistochemistry and enzyme-linked immunosorbent assay. Receiver operating characteristic (ROC) curves were performed to determine the predictive value of SAA in nasal polyps. The clinical characteristics of 2 CRSwNP subtypes (SAA^high and SAA^low) were evaluated.

Results

The SAA expression levels in polyp tissues were significantly elevated both in non-eosinophilic and eosinophilic CRSwNP as compared to the healthy controls. In patients with CRSwNP, the tissue SAA level was significantly higher in the disease-controlled patients than those of the partly controlled and uncontrolled. ROC curve analysis revealed that a cut-off value of 114.9 ng/mL for the tissue SAA level predicted the patients with disease-controlled status with 93.33% sensitivity and 63.64% specificity (AUC = .8727, P < .001). Furthermore, The SAA^high subgroup showed higher tissue eosinophil numbers and percentage of the disease-controlled patients compared to the SAA^low subgroup.

Conclusions

Our findings suggest that measurements of SAA in polyp tissues may provide useful information for evaluating CRSwNP conditions, especially identifying the CRSwNP patients with disease-controlled status after endoscopic sinus surgery.

Keywords

chronic rhinosinusitis nasal polyps serum amyloid A disease control

Introduction

Chronic rhinosinusitis (CRS) is a chronic inflammatory disease of the mucosa of the nose and paranasal sinuses. Based on the presence or absence of polyp formation, CRS is typically classified into 2 clinical phenotypes, CRS with nasal polyps (CRSwNP) and CRS without nasal polyps.¹ Although only accounting for ∼25-30% of patients with CRS, CRSwNP patients usually have greater severity of clinical disease and impairment of quality of life as well as cost burden compared to those without nasal polyps, making it more clinically challenging to rhinology clinicians.^1-6 There are several treatment modalities for CRSwNP proposed by mainstay guidelines, including comprehensive medical therapy and endoscopic sinus surgery, with the main goal of achieving and maintaining clinical disease control.^1,2 However, we and others have reported that over 30% of patients with CRSwNP remain uncontrolled despite current standard-of-care treatment.^7-9 Evidence has emerged suggesting that it may be caused by an underlying variation of endotypes resulting in a discrepancy of clinical phenotype and disease prognosis.^10-13 Thus, the need for seeking new relevant biomarkers in patients with good or poor disease control is generally acknowledged.

Serum amyloid A (SAA) is a secreted protein first characterized for its role in the acute-phase response to inflammation and therefore has been a clinical biomarker for active inflammation.¹⁴ In addition, studies also have shown that SAA levels are remarkably elevated in patients with a broad spectrum of chronic inflammatory diseases, such as atherosclerosis,¹⁵ allergic asthma,¹⁶ and CRSwNP.¹⁷ Although the biological functions of SAA in immunity and inflammation are poorly defined, previous studies have suggested that SAA participates in inflammatory responses as a chemokine of immune cells such as monocytes, neutrophils, dendritic cells, and T lymphocytes.^14,18-22 Furthermore, in vitro studies showed that SAA stimulation of leukocytes resulted in increased production of proinflammatory cytokines including IL-1β, IL-6, and TNFα,¹⁴ suggesting SAA may be involved in the inflammatory response through immune cell activation. The clinical applications of SAA have been highlighted. A series of publications have demonstrated the association of SAA with neutrophilic inflammation and Th17 immune response in airway diseases including chronic obstructive pulmonary disease (COPD),²³ allergic asthma,²⁴ and CRSwNP.¹⁷ Recently, we further revealed that SAA levels in polyp tissues could serve as a biomarker for the prediction of corticosteroid insensitivity in patients with CRSwNP.²⁵ Since it has been well recognized that corticosteroid responsiveness is closely related to the degree of eosinophilic inflammation, whereas eosinophilic inflammation is a major phenotype associated with poorly controlled disease and polyp recurrence in patients with CRSwNP,^26-28 this led us to hypothesize that SAA might be used as a potential biomarker for predicting treatment outcome in patients with CRSwNP after endoscopic sinus surgery. The aims of this study were, first, to compare SAA levels in polyp tissues in CRSwNP subjects during different conditions defined as controlled, partly controlled and uncontrolled, and second, to evaluate whether SAA levels could be a biomarker of disease control in CRSwNP.

Patients and Methods

Patients and Tissue Samples

This study was approved by the Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University. Written informed consent was obtained from all participants. Patients with a diagnosis of bilateral CRSwNP based on the European position paper on rhinosinusitis and nasal polyps (EPOS 2012)²⁹ and performed transnasal endoscopic surgery were identified from the electronic medical database of the First Affiliated Hospital of Sun Yat-sen University between January 2015 and December 2016. All patients were under a current standard-of-care treatment and follow-up according to the Chinese and European position papers.^29,30 Patients with following criteria were excluded: (1) Patients without adequate polyp specimens. (2) Patients lacked of data of baseline blood routine test, nasal endoscopy, and sinus computed tomography (CT). (3) Patients treated with systemic or intranasal corticosteroids within 3 months and 1 month before blood routine test, respectively, by cross-referencing patient’s medication history with the electronic prescription record system. (4) Patients less than 16 years. (5) Patients with a history of food allergies, allergic dermatitis, or worm infection. (6) Patients with fungal rhinosinusitis, cystic fibrosis, gastro-esophageal refiux disease, or sinonasal malignancies. Control subjects were patients undergoing optic nerve decompression because of traumatic optic neuropathy without any nasal disease. Allergic rhinitis was diagnosed according to the Allergic Rhinitis and its Impact on Asthma guideline.³¹ The diagnosis of asthma was established based on the Global Initiative for Asthma guideline by a specialist physician.³² The diagnosis of aspirin sensitivity was based on the documented history of intake of aspirin or non-steroid inciting worsening respiratory symptoms. Lund-Mackay score was performed by a trained researcher through scoring of CT images.³³

Clinical Assessment of Disease Control

Patients enrolled were followed up for the assessment of clinical disease control level based on the classification criteria of EPOS 2012 (Supplementary Table 1) by 2 senior authors (Y. S. and J. S.),²⁹ which has been validated by our and other groups.^7-9 Briefly, CRS control status was stratified into 3 levels: controlled, partly controlled, and uncontrolled. Controlled CRS was established based on no bothersome symptoms, with healthy or almost healthy mucosa and no need for systemic medicine to control disease. Partly controlled patients experienced less than 2 of the following items: persistent nasal blockage, mucopurulent rhinorrhea/postnasal drip, facial pain, impaired smell, sleep disturbance/fatigue, disease mucosa under nasal endoscopy, and the need for a course of antibiotics/systemic corticosteroids in the last months. Uncontrolled CRS was diagnosed as 3 or more features of partly controlled CRS.

Histopathologic Evaluation

Polyp tissues and uncinate process mucosa were taken from CRSwNP patients and control subjects during endoscopic surgery, respectively. Samples were fixed in 10% formalin, embedded in paraffin, cut in 4-μm sections and stained with hematoxylin–eosin. The stained sections were observed using a microscope (Leica DM4 B; Leica, Wetzlar, Germany) by 2 independent observers in a blinded fashion to clinical data. Cell counting was performed as we previously reported.⁷ Top 5 densest cellular infiltrate areas of the subepithelial layer were chosen for cell counting for each specimen under low power field (100×). Then eosinophils and total inflammatory cells were quantified in the focus of each area under high power field (400×, .072 mm²/frame, HPF). Eosinophil and total inflammatory cell count were recorded in each focus field at 400 power and reported as absolute number per HPF. Eosinophilic CRSwNP (ECRSwNP) was diagnosed when the percentage of tissue eosinophils exceeded 10% of the total inflammatory cells according to the European guideline.²

Serum Amyloid A Immunohistochemical Staining

Immunohistochemical staining was performed using the standardized procedures as we previously described.²⁵ Briefly, sections were deparaffinized by serial treatment. After inhibiting the endogenous peroxidase in 3% hydrogen peroxide and with 1% bovine serum albumin, the sections were incubated overnight at 4°C in the presence of a mouse anti-human SAA monoclonal antibody (Abcam, Cambridge, MA, USA) at a dilution of 1:100 according to the manufacturer’s instructions. Each of these sections was incubated with a secondary antibody and then with horseradish peroxidase-labeled streptavidin complex (Zhongshanjinqiao, Beijing, China). Distribution of peroxidase was revealed by incubating the sections in a solution containing 3% 3,3^′-diaminobenzidine tetrahydrochloride before being counterstained with hematoxylin and cover slipped. Negative control studies were performed by omitting the incubation step with the primary antibody.

Enzyme-Linked Immunosorbent Assay

Fresh polyp tissues and uncinate process mucosa samples were weighed and placed in PBS-Tween supplemented with a protease inhibitor cocktail (Keygentec, Nanjing, Jiangsu, China), and homogenized for 1 min on ice. The samples were then centrifuged at 4000 rpm for 20 min at 4°C, and the supernatants were stored at −20°C until ELISA analysis. The SAA concentrations were measured with commercially available ELISA (ab100635, Abcam) according to the manufacturer’s instructions. Detection limits were .41 ng/mL of SAA.

Statistical Analysis

GraphPad Prism 6 software (San Diego, CA, USA) was used for statistical analyses. T tests and one-way ANOVA and Tukey’s multiple comparisons post hoc tests were used for continuous variables with normal distribution. Mann–Whitney U tests were used for continuous non-normally distributed variables. χ2 Tests were used to assess differences in categorical variables, such as gender or smoking prevalence. The predictive ability of tissue SAA protein level was evaluated by receiver operating characteristic (ROC) curve. A P value less than .05 was considered as statistically significant.

Results

Characteristics of Participants

Forty-eight patients with CRSwNP and ten healthy control subjects followed for a median time of 86.4 weeks were included. The clinical characteristics of the study subjects are presented in Supplementary Table 2. Twenty-six patients and twenty-two patients were non-ECRSwNP and ECRSwNP, respectively. Age, gender, and smoking status were matched between the study groups. The comorbidity rates of allergic rhinitis and asthma in patients with ECRSwNP were higher than those in non-ECRSwNP and healthy controls. Consistent to previous reports,^7,8,10,28,34 patients with ECRSwNP had significantly higher preoperative CT score, blood and tissue eosinophil numbers, and percentage of uncontrolled disease after endoscopic sinus surgery.

Association of SAA Expression With Disease Control Status in Patients With CRSwNP

We first compared the protein level of SAA in nasal tissues between patients with non-ECRSwNP, ECRSwNP, and healthy controls. By doing IHC staining, strong immunoreactivity of SAA was observed both in non-ECRSwNP and ECRSwNP. Consistent with our previous observations,^17,25 the SAA immunoreactivity was mainly observed in the epithelial layer of polyp tissues. Additionally, subepithelial inflammatory cells and glands were also displayed scattered positive staining. By contrast, the SAA immunoreactivity was relatively weak in the healthy controls (Figure 1A). Consistently, the SAA protein levels in polyp tissues as evaluated by ELISA were significantly elevated both in non-ECRSwNP and ECRSwNP as compared to the healthy controls (P < .001 and .01, respectively) (Figure 1B).

Figure 1.

Increased expression of SAA in CRSwNP. (A) Representative immunohistochemical staining of SAA in non-ECRSwNP, ECRSwNP, and healthy control. Original magnification: ×400. The protein level (B) of SAA in non-ECRSwNP, ECRSwNP, and healthy control assessed by ELISA. **P < .01; ***P < .001.

Next, we compared the expression of SAA in polyp tissues between CRSwNP patients with different disease control level. We found that the disease-controlled patients had the strongest immunoreactivity of SAA in polyp tissues (Figure 2A). ELISA analysis confirmed that the SAA level was significantly higher in polyp tissues of the disease-controlled patients than those of the partly controlled and uncontrolled (P < .001 and .01, respectively) (Figure 2B). There was no significant difference in the level of SAA in polyp tissues between the partly controlled and the uncontrolled.

Figure 2.

Differential expression of SAA in CRSwNP patients with different disease status. (A) Representative immunohistochemical staining of SAA in CRSwNP patients with controlled, partly controlled, and uncontrolled status. Original magnification: ×400. The protein level (B) of SAA in CRSwNP patients with controlled, partly controlled, and uncontrolled status assessed by ELISA. ***P < .001.

We further performed the ROC curve analysis to determine the predictive ability of tissue SAA level (Figure 3). The results showed that the area under the curve (AUC) of tissue SAA protein level is .8727 (95% CI .7736-.9719), suggesting a strong predictive value for disease-controlled status. When the tissue SAA protein level was 114.9 ng/mL or higher, the sensitivity and specificity were 93.33% and 63.64%, respectively.

Figure 3.

The ROC curve for polyp SAA protein levels. AUC of polyp SAA protein level was .8727 (95% CI .7736-.9719). ROC, receiver operating characteristic; SAA, serum amyloid A; AUC, area under the ROC curve; CI, confidence interval.

Characteristics of CRSwNP Patients With High SAA Expression

To characterize the CRSwNP patients with high SAA expression, we next subdivided the CRSwNP patients into SAA^high and SAA^low subgroups according to the SAA cut-off value of 114.9 ng/mL in polyp tissues. As a result, there were 22 and 26 SAA^high and SAA^low CRSwNP patients, respectively. Surprisingly, we found that the tissue eosinophil count and percentage were significantly higher in the SAA^high CRSwNP patients than those in the SAA^low CRSwNP patients (Figure 4 and Table 1, both P < .05). No significant difference in age, gender, smoking status, percentage of allergic rhinitis and asthma, preoperative CT score, and blood eosinophil numbers were observed.

Figure 4.

Different eosinophilic numbers in the SAA^high and SAA^low polyp tissues. HPF high power field.

Table 1.

Comparison of Demographics, Comorbidities, and Clinical Features Between Patients in SAA^high and SAA^low Subgroups.

<!—Col Count:4-->	SAA^high subgroup	SAA^low subgroup	P value
Subject number	22	26
Male, n (%)	19 (73.1%)	11 (54.5%)	.232
Age, mean (SD)	38.1±14.3	38.3±15.1	.710
Current smoker, n (%)	3 (11.5%)	0 (0)	.239
Allergic rhinitis, n (%)	2 (7.7%)	5 (22.7%)	.223
Asthma, n (%)	1 (3.8%)	4 (18.2%)	.165
Preoperative L-M CT score, median (IQR)	14.0 (10.25)	15.0 (10.0)	.181
Blood eosinophil count, median (IQR) (×10⁹/L)	.195 (.27)	.29 (.34)	.466
Blood eosinophil percentage, median (IQR)	.031 (.051)	.051 (.049)	.215
Tissue eosinophil count, median (IQR) (/HPF)	80.0 (182.3)	27.5 (30.0)	.032
Tissue eosinophil percentage, median (IQR)	.218 (.448)	.068 (.1)	.019
Treatment outcome			<.001
Controlled, n (%)	14 (53.8%)	1 (4.5%)
Partly controlled, n (%)	9 (34.6%)	9 (40.9%)
Uncontrolled, n (%)	3 (11.5%)	12 (54.5%)

Abbreviations: SD, standard deviation; IQR, interquartile range; HPF, high power field; SAA, serum amyloid A.

The disease-controlled patients accounted for 53.8% and 4.5%, whereas the disease-uncontrolled patients 11.5% and 54.5% of patients in SAA^high and SAA^low subgroup, respectively (Figure 5 and Table 1). The percentages of patients in the 3 categories of disease control status were significantly different between SAA^high and SAA^low subgroup (Table 1).

Figure 5.

Distinct treatment outcome between the SAA^high and SAA^low CRSwNP patients. The percentages of patients in the 3 categories of disease control status were significantly different between SAA^high and SAA^low subgroup (P<.001).

Discussion

Our previous studies reported that SAA expression is remarkably elevated in CRSwNP patients, and its level in polyp tissues has potential value in predicting systemic corticosteroid insensitivity in patients with CRSwNP.^17,25 Here, we extended our previous studies and found that the tissue SAA levels were significantly higher in both non-ECRSwNP and ECRSwNP compared to the healthy subjects. In addition, the tissue SAA levels were further elevated in the patients with disease-controlled compared to those with the disease partly controlled and uncontrolled. Furthermore, ROC and AUC analysis showed that the SAA expression level was identified as a reliable predictor of the disease-controlled patients with CRSwNP. At a SAA level of 114.9 ng/mL or higher for predicting patients with disease-controlled status, the sensitivity reached 93.33%, and the specificity was 63.64%. These preliminary results suggest that the SAA level in polyp tissues could be served as a supplementary predictor for disease control assessment in patients with CRSwNP after endoscopic sinus surgery.

Chronic rhinosinusitis with nasal polyps with different pathological endotypes could display significant differences in their treatment outcome after comprehensive medical therapy and endoscopic sinus surgery. Therefore, identification of additional clinical parameters and biomarkers that could supplement the current understanding of clinical response prediction in patients with CRSwNP would greatly improve the therapy and follow-up of the disease. For this purpose, previous studies have revealed several predictors of the patients with disease uncontrolled status or polyp recurrence, including tissue and blood eosinophils,^7,34 Charcot–Leyden crystals,³⁵ interleukin (IL)-5,³⁶ sinus CT score,³⁷ comorbid asthma.³⁸ However, few studies have explored factors related to the patients with good controlled status. In the present study, we showed that the SAA level in nasal polyps had a high diagnostic accuracy in identifying the patients with disease-controlled status, adding the potential clinical application value of measurement of tissue SAA for the prediction of corticosteroid insensitivity as well as supplementing the current prediction parameters. Additionally, to our knowledge, our study also provided the first evidence that increased tissue SAA levels is associated with a better prognosis in patients with CRSwNP after endoscopic sinus surgery.

During various inflammatory conditions, SAA is mainly produced in the liver and plays an important role in host defense by chemoattracting innate and adaptive immune cells, such as monocytes, neutrophils, and T lymphocytes, and inducing the production of proinflammatory cytokines, such as IL-1β, IL-8, and TNF-a, through binding to the SAA receptor formyl peptide receptor-like 1.^14,20 Recent studies explored its potential value as a biomarker for translational applications. Lin et al revealed that serum SAA levels were elevated in patients with acutely exacerbated COPD and could be used as an effective index for the diagnosis and severity assessment of acutely exacerbated COPD.³⁹ Our group showed that SAA levels in polyp tissues could serve as a biomarker for the prediction of corticosteroid insensitivity in patients with CRSwNP.²⁵ In the current study, we further showed that tissue SAA levels were able to predict the CRSwNP patients with disease-controlled status after endoscopic sinus surgery with a high accuracy. Together, these studies highlight the promising application of SAA in serving as a potential diagnostic biomarker in CRSwNP.

In our previous study, we showed that tissue SAA level was positively associated with the neutrophil number in patients with CRSwNP.²⁵ This, together with the findings of the present study, is somewhat conflicted with recent endotype-focused studies. Delemarre et al showed that severe eosinophilic type 2 CRSwNP was frequently associated with a severe neutrophilic inflammation.⁴⁰ Furthermore, Kim et al found that tissue neutrophilia was associated with disease refractoriness in patients with CRSwNP.⁴¹ However, similar findings were not observed in the study by Rosati et al, where neutrophilic infiltration and IL-8 expression did not correlate with the rate of polyp recurrence in CRSwNP patients.⁴² The reason for these discrepancies remains unclear. However, it is possible that SAA, mainly produced by epithelial cells and acts as an upstream signal of neutrophilic inflammation, is unable to comprehensively represent the neutrophilic inflammation in CRSwNP, where reciprocal interactions between eosinophils and neutrophils play an important role in the disease persistency and severity.⁴³

In addition, we surprisingly found that the SAA^high CRSwNP patients had higher numbers of tissue eosinophils than those of the SAA^low CRSwNP patients (Figure 4 and Table 1). This seems to conflict with previous observations that the patients with high eosinophil numbers tend to have higher disease recurrence rates.^34,44 However, it should be noted that the tissue eosinophil counts and percentages of the SAA^high CRSwNP patients were still significantly lower than their counterpart of the eosinophilic CRSwNP (Supplementary Table 2). Further prospective studies are needed to compare the difference in the relationship between SAA, eosinophils, and the treatment outcome in CRSwNP patients.

The present study is subjected to several limitations. The major one is the retrospective nature of the present study, in which a systematic selection bias could be introduced, thus possibly contributing to the observation that the SAA^high CRSwNP patients had higher numbers of tissue eosinophils than those of the SAA^low CRSwNP patients. Moreover, the patients in this study were all recruited from a tertiary academic hospital and may not be representative of other medical care settings. Although we showed that measurement of tissue SAA level was able to identify the disease-controlled patients with CRSwNP, its clinical predictive value remained to be validated. In the future, a multi-center and prospective follow-up study with a larger cohort is eagerly warranted.

In conclusion, increased tissue SAA levels are associated with a better prognosis in patients with CRSwNP after endoscopic sinus surgery. Measurements of SAA in polyp tissues may provide useful information for evaluating CRSwNP conditions, especially identifying the CRSwNP patients with disease-controlled status after endoscopic sinus surgery.

Supplemental Material

Supplemental Material - Association Between Serum Amyloid A Expression and Disease Control after Endoscopic Sinus Surgery in Patients With Chronic Rhinosinusitis With Nasal Polyps

Supplemental Material for Association Between Serum Amyloid A Expression and Disease Control after Endoscopic Sinus Surgery in Patients With Chronic Rhinosinusitis With Nasal Polyps by Hangui Lu, Haiyan Liu, Kanghua Wang, Jianbo Shi and Yueqi Sun in Ear, Nose & Throat Journal

Footnotes

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by grants from the Guangdong Basic and Applied Basic Research Foundation (2020A1515010134 and 2019A1515011029).

ORCID iD

Yueqi Sun

Supplemental Material

Supplemental material for this article is available online.

References

Orlandi

Kingdom

Smith

, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol. 2021;11(3):213-739.

Fokkens

Lund

Hopkins

, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(Suppl S29):1-464.

Stevens

Schleimer

Kern

. Chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2016;4(4):565-572.

Bhattacharyya

Villeneuve

Joish

, et al. Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps. Laryngoscope. 2019;129(9):1969-1975.

Lourijsen

Fokkens

Reitsma

. Direct and indirect costs of adult patients with chronic rhinosinusitis with nasal polyps. Rhinology. 2020;58(3):213-217.

Rudmik

Smith

Schlosser

Hwang

Mace

Soler

. Productivity costs in patients with refractory chronic rhinosinusitis. Laryngoscope. 2014;124(9):2007-2012.

Wang

Deng

Yang

, et al. Concordant systemic and local eosinophilia relates to poorer disease control in patients with nasal polyps. World Allergy Organ J. 2019;12(8):100052.

Tao

Chen

Sun

, et al. Prediction models for postoperative uncontrolled chronic rhinosinusitis in daily practice. Laryngoscope. 2018;128(12):2673-2680.

van der Veen

Seys

Timmermans

, et al. Real-life study showing uncontrolled rhinosinusitis after sinus surgery in a tertiary referral centre. Allergy. 2017;72(2):282-290.

10.

Liao

Liu

, et al. Multidimensional endotypes of chronic rhinosinusitis and their association with treatment outcomes. Allergy. 2018;73(7):1459-1469.

11.

Tomassen

Vandeplas

Van Zele

, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137(5):1449-1456.

12.

Akdis

Bachert

Cingi

, et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2013;131(6):1479-1490.

13.

Bachert

Marple

Hosemann

Cavaliere

Wen

Zhang

. Endotypes of chronic rhinosinusitis with nasal polyps: pathology and possible therapeutic implications. J Allergy Clin Immunol Pract. 2020;8(5):1514-1519.

14.

Sun

. Emerging functions of serum amyloid A in inflammation. J Leukoc Biol. 2015;98(6):923-929.

15.

Getz

Krishack

Reardon

. Serum amyloid A and atherosclerosis. Curr Opin Lipidol. 2016;27(5):531-535.

16.

Ozseker

Buyukozturk

Depboylu

, et al. Serum amyloid A (SAA) in induced sputum of asthmatics: a new look to an old marker. Int Immunopharm. 2006;6(10):1569-1576.

17.

Wang

Bai

Ding

, et al. Interleukin-17A contributes to the expression of serum amyloid A in chronic rhinosinusitis with nasal polyps. Eur Arch Otorhinolaryngol. 2013;270(6):1867-1872.

18.

Sozzani

Del Prete

. Chemokines as relay signals in human dendritic cell migration: serum amyloid A kicks off chemotaxis. Eur J Immunol. 2015;45(1):40-43.

19.

De Buck

Gouwy

Berghmans

, et al. COOH-terminal SAA1 peptides fail to induce chemokines but synergize with CXCL8 and CCL3 to recruit leukocytes via FPR2. Blood. 2018;131(4):439-449.

20.

De Buck

Gouwy

Wang

, et al. The cytokine-serum amyloid A-chemokine network. Cytokine Growth Factor Rev. 2016;30:55-69.

21.

Abouelasrar Salama

De Bondt

De Buck

, et al. Serum amyloid A1 (SAA1) revisited: restricted leukocyte-activating properties of homogeneous SAA1. Front Immunol. 2020;11:843.

22.

Gouwy

De Buck

Portner

, et al. Serum amyloid A chemoattracts immature dendritic cells and indirectly provokes monocyte chemotaxis by induction of cooperating CC and CXC chemokines. Eur J Immunol. 2015;45(1):101-112.

23.

Bozinovski

Uddin

Vlahos

, et al. Serum amyloid A opposes lipoxin A(4) to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease. Proc Natl Acad Sci U S A. 2012;109(3):935-940.

24.

Ather

Ckless

Martin

, et al. Serum amyloid A activates the NLRP3 inflammasome and promotes Th17 allergic asthma in mice. J Immunol. 2011;187(1):64-73.

25.

Lin

Yao

, et al. Increased serum amyloid A in nasal polyps is associated with systemic corticosteroid insensitivity in patients with chronic rhinosinusitis with nasal polyps: a pilot study. Eur Arch Otorhinolaryngol. 2018;275(2):401-408.

26.

Gurrola

2nd Borish

. Chronic rhinosinusitis: endotypes, biomarkers, and treatment response. J Allergy Clin Immunol. 2017;140(6):1499-1508.

27.

Fujieda

Imoto

Kato

, et al. Eosinophilic chronic rhinosinusitis. Allergol Int. 2019;68(4):403-412.

28.

Lou

Zhang

Bachert

Zhang

. Highlights of eosinophilic chronic rhinosinusitis with nasal polyps in definition, prognosis, and advancement. Int Forum Allergy Rhinol. 2018;8(11):1218-1225.

29.

Fokkens

Lund

Mullol

, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50(1):1-12.

30.

Liu

Chen

Cheng

, et al. Chinese society of allergy and chinese society of otorhinolaryngology-head and neck surgery guideline for chronic rhinosinusitis. Allergy Asthma Immunol Res. 2020;12(2):176-237.

31.

Bousquet

Khaltaev

Cruz

, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86)):8-160.

32.

Bateman

Hurd

Barnes

, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31(1):143-178.

33.

Lund

Kennedy

. Quantification for staging sinusitis. The staging and therapy group. Ann Otol Rhinol Laryngol Suppl. 1995;104:17-21.

34.

Lou

Meng

Piao

Wang

Zhang

Bachert

. Predictive significance of tissue eosinophilia for nasal polyp recurrence in the Chinese population. Am J Rhinol Allergy. 2015;29(5):350-356.

35.

Yan

Liu

Wang

Zhang

. Predictive significance of Charcot-Leyden Crystal mRNA levels in nasal brushing for nasal polyp recurrence. Rhinology. 2020;58(2):166-174.

36.

Nakayama

Asaka

Kanaya

Kuboki

Haruna

. Prognostic factors for recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps. Auris Nasus Larynx. 2016;43(6):641-647.

37.

Meng

Zhang

Lou

Wang

. Predictive value of computed tomography in the recurrence of chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2019;9(11):1236-1243.

38.

Zhang

Linkin

Finkelman

, et al. Asthma and biofilm-forming bacteria are independently associated with revision sinus surgeries for chronic rhinosinusitis. J Allergy Clin Immunol. 2011;128(1):221-223.

39.

Lin

Chen

Ding

Wei

Huang

. Correlations between serum amyloid A, C-reactive protein and clinical indices of patients with acutely exacerbated chronic obstructive pulmonary disease. J Clin Lab Anal. 2019;33(4):e22831.

40.

Delemarre

Holtappels

De Ruyck

, et al. A substantial neutrophilic inflammation as regular part of severe type 2 chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2021;147(1):179-188.

41.

Kim

Han

, et al. Elastase-positive neutrophils are associated with refractoriness of chronic rhinosinusitis with nasal polyps in an Asian population. Allergy Asthma Immunol Res. 2020;12(1):42-55.

42.

Rosati

Rosato

Pagliuca

, et al. Predictive markers of long-term recurrence in chronic rhinosinusitis with nasal polyps. Am J Otolaryngol. 2020;41(1):102286.

43.

Delemarre

Bochner

Simon

Bachert

. Rethinking neutrophils and eosinophils in chronic rhinosinusitis. J Allergy Clin Immunol. 2021;148:327-335.

44.

Tokunaga

Sakashita

Haruna

, et al. Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC Study. Allergy. 2015;70(8):995-1003.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.10 MB